<DOC>
	<DOC>NCT01841775</DOC>
	<brief_summary>Multicenter prospective follow-up of a not controlled chronic hepatitis C genotypes 2/3 patients cohort with treatment indication with interferon α 2b and ribavirin for 24 weeks, and the verification of sustained virological response at week 48. The eligibility criteria and outcome measures followed the Clinical Protocol and Therapeutic Guidelines for Chronic Viral Hepatitis C, published by the Ministry of Health: http://portal.saude.gov.br/portal/arquivos/pdf/pcdt_hepatite_c_2011_retificado.pdf</brief_summary>
	<brief_title>Interferon α 2b Pharmacovigilance Study</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Genotype 2/3 Chronic Hepatitis C confirmed by biomolecular technology (RNAVHC); Treatment naive; Signing the Informed Consent Form; Eligibility criteria and outcome measures followed the Clinical Protocol and Therapeutic Guidelines for Chronic Viral Hepatitis C, published by the Ministry of Health: http://portal.saude.gov.br/portal/arquivos/pdf/pcdt_hepatite_c_2011_retificado.pdf Serious adverse events; Intolerance to treatment; Lost to follow up.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Hepatitis C, Chronic</keyword>
	<keyword>Genotype 2/3</keyword>
	<keyword>Interferon α 2b</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Pharmacovigilance</keyword>
</DOC>